Press release
Glioma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | CellabMED, Oblato, BioMed Valley Discoveries, PharmAbc
Glioma Pipeline Analysis
Glioma Pipeline constitutes 180+ key companies continuously working towards developing 200+ Glioma treatment therapies, analyzes DelveInsight.
Glioma Overview:
Gliomas are tumors that originate in the glial cells of the brain or spinal cord, which support the nervous system. They are the most common type of central nervous system (CNS) tumors and are known for their infiltrative nature. Gliomas are classified based on the type of glial cell involved-astrocytes, oligodendrocytes, or ependymal cells-and vary in severity from low-grade (slow-growing) to high-grade (aggressive and malignant).
Historically, classification relied on histopathological features like diffuse astrocytomas or oligodendrogliomas. However, modern approaches emphasize molecular and genetic markers for more accurate diagnosis, prognosis, and treatment planning. Gliomas are graded on a scale from I to IV, depending on cell proliferation and the presence of necrosis. The three main types include astrocytomas, oligodendrogliomas, and ependymomas, and are further grouped into low-grade (grades I-II) and high-grade (grades III-IV) based on their biological behavior and molecular features. Glioblastoma is the most aggressive form, while pilocytic astrocytoma is the least malignant.
Request for a detailed insights report on Glioma pipeline insights [https://www.delveinsight.com/report-store/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Glioma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioma Therapeutics Market.
Key Takeaways from the Glioma Pipeline Report
*
DelveInsight's Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.
*
In April 2025, Boston Scientific Corporation initiated the FRONTIER feasibility study to assess the safety of the TheRaSphere Glioblastoma (GBM) device in patients with recurrent GBM. Glioblastoma (GBM) is an extremely aggressive brain cancer with a poor prognosis.
*
Key Glioma companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, Day One Biopharmaceuticals, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen, and others are evaluating new drugs for Glioma to improve the treatment landscape.
*
Promising Glioma pipeline therapies in various stages of development include ONC 201, Enzastaurin, MDNA55, Safusidenib, CAN-3110, MB-101, and others.
Glioma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Glioma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Glioma market.
Download our free sample page report on Glioma pipeline insights [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Glioma Emerging Drugs
*
ONC 201: Chimerix
*
Enzastaurin: Denovo BioPharma
*
MDNA55: Medicenna Therapeutics, Inc.
*
Safusidenib: AnHeart Therapeutics
*
CAN-3110: Candel Therapeutics
*
MB-101: Mustang Bio
Glioma Companies
More than 180 leading companies are actively working on developing treatments for Glioma. Among them, Biohaven Pharmaceuticals, Inc. has the most advanced drug candidates, currently in Phase III clinical trials.
DelveInsight's report covers around 200+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Glioma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Glioma Therapies and Key Companies: Glioma Clinical Trials and advancements [https://www.delveinsight.com/report-store/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Glioma Pipeline Therapeutic Assessment
- Glioma Assessment by Product Type
- Glioma By Stage
- Glioma Assessment by Route of Administration
- Glioma Assessment by Molecule Type
Download Glioma Sample report to know in detail about the Glioma treatment market @ Glioma Therapeutic Assessment [https://www.delveinsight.com/sample-request/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioma Current Treatment Patterns
4. Glioma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioma Late-Stage Products (Phase-III)
7. Glioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioma Discontinued Products
13. Glioma Product Profiles
14. Glioma Key Companies
15. Glioma Key Products
16. Dormant and Discontinued Products
17. Glioma Unmet Needs
18. Glioma Future Perspectives
19. Glioma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the GliomaO Pipeline Reports Offerings [https://www.delveinsight.com/report-store/glioma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioma-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-cellabmed-oblato-biomed-valley-discoveries-pharmabc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioma Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | CellabMED, Oblato, BioMed Valley Discoveries, PharmAbc here
News-ID: 4100152 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Glioma
Glioma Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent advances…
Glioma Competitive Landscape 2023 (Updated)
DelveInsight's, "Glioma Competitive Landscape 2023" report provides comprehensive insights about 200+ Glioma companies and 220+ drugs in Glioma Competitive landscape. It covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Competitive Landscape Report
• DelveInsight's Glioma report depicts a robust space with 200+ Glioma companies working to develop 220+ pipeline therapies…
Low-Grade Glioma Therapeutics Market - Transforming Futures, Defying Low-Grade G …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Low-Grade Glioma Therapeutics Market.
Low-Grade Glioma Therapeutics Market: https://www.growthplusreports.com/report/lowgrade-glioma-therapeutics-market/9187
The Low-Grade Glioma Therapeutics Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the…
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers…
Glioma pipeline involves 150+ key companies continuously working towards develop …
DelveInsight's, "Glioma Pipeline Insight, 2023," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's glioma pipeline report depicts a…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
